e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors.

The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday.

Following the proposed issue, the company will have a pro-forma net cash and liquid resources of approximately £48m.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

According to the the company's update, the resources are intended to support its currently planned discovery and development activities to 2017, by which time, it said it believed that an out-licensing deal could be concluded for the company's lead cancer drug ETS2101.

Professor Malcolm Young Chief Executive Officer of e-Therapeutics, said: "We appreciate the continuing support of existing investors and are also pleased to have attracted significant new investors to the company. With our financial position secure, we are well-placed to build further shareholder value based on our innovative platform and product portfolio."

e-Therapeutics' share price was up 4.88% to 32.25p at 09:03 on Monday.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.